CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that CEO Frank Reynolds is scheduled to appear on KXAN-TV’s Austin News Today Weekend on Saturday, May 19th at 7:20am CDT in Austin, TX. He is also scheduled to appear on Detroit’s WXYZ-TV 7 Action News on Sunday, May 20th at 8:40am EDT with local quadriplegic Drew Clayborn. Drew was paralyzed in 2010 and will join Frank on air to talk about his story and how InVivo Therapeutics’ treatment could change his life.
InVivo Therapeutics has pioneered a new treatment using a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord. The device spares spinal cord tissue from scarring while improving functional recovery after a traumatic SCI. In addition to the scaffold and its application for acute and chronic SCI, Reynolds will discuss new hydrogel technologies under development by InVivo.
“Our technology is a true platform that can be leveraged to create many Neurotrauma products. InVivo is developing technologies to treat chronic injuries like Drew’s, as well as therapies for other nervous system conditions such as chronic pain due to nerve compression and other peripheral nerve injuries. We’re currently under review at FDA for our first SCI treatment, and we look forward to receiving approval to begin those human studies in 2012,” said Reynolds.
Austin News Today Weekend airs on Saturday and Sundays from 7:00-9:00am CDT on KXAN-TV, the local NBC affiliate for the greater Austin, TX area. 7 Action News This Weekend airs on Saturday and Sunday mornings from 6:00-7:00am and 8:00-9:30am EDT on WXYZ-TV, the local ABC affiliate in Detroit, MI.
The financial impact of SCI, as reported by the National Spinal Cord Injury Statistical Center, is staggering, and the lifelong cost of care for a quadriplegic can exceed $4 million. Drew’s medical costs continue to mount quickly and all donations are greatly appreciated. If you want to help, please visit www.thedrewcrew.net.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.